Taking raloxifene reduces the risk of breast cancer

Early results of a US medical study show that a drug being used to treat osteoporosis also works to reduce the risk of breast cancer. Moreover, it is less likely to cause side effects like the drug Tamoxifen, which is used to treat this disease.

Reloxifene has been marketed, under the Evista brand as a drug for osteoporosis (Photo: lilly) Tamoxifen is often indicated for the prevention of breast cancer, but postmenopausal women have The risk of breast cancer is high, it is often avoided because of its side effects.

And the good news came to them when researchers announced that women who took Raloxifene, a drug for osteoporosis treatment, would be less likely to develop breast cancer . This statement came after testing over 20,000 women, most of whom were menopausal at a high risk of breast cancer, including those of the same age group. 60 and people with family members have breast cancer.

During the study, two types of drugs were compared and found that regular use of the drug within five years halved the risk of malignant breast cancer.

According to Dr. Mary Daly of Fox Chase Cancer Center, Raloxifene works to prevent female hormones , which are essential for breast cancer growth.

Raloxifene also causes some side effects but not as much as Tamoxifene. Users of Raloxifene had 36% fewer cases of uterine cancer, and 29% had less hematoma than Tamoxifene users. Raloxifene users are also less likely to develop cataracts.

Currently the pharmaceutical manufacturer Eli Lilly has sold reloxifene to the market, under the brand Evista as a drug for osteoporosis. With this study, Lilly is planning to get permission from the US Food and Drug Administration to market Raloxifene as a breast cancer drug.